Astrazeneca Plc (NYSE:AZN) Stock Has Consensus Target Price of $206.67 According to Analysts

Posted by George Bondi on Oct 15th, 2026

Shares of Astrazeneca Plc (NYSE:AZN – Get Free Report) have received an average rating of “Moderate Buy” from the nineteen brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and fifteen have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $206.67.

AZN has been the topic of a number of research analyst reports. CICC Research began coverage on shares of Astrazeneca in a report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective on the stock. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Nordea Equity Research upgraded Astrazeneca from a “sell” rating to a “buy” rating in a research note on Tuesday. Finally, Wall Street Zen cut Astrazeneca from a “buy” rating to a “hold” rating in a research report on Sunday.

Read Our Latest Analysis on Astrazeneca

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Mather Group LLC. boosted its holdings in shares of Astrazeneca by 14.0% in the 3rd quarter. Mather Group LLC. now owns 1,697 shares of the company’s stock valued at $274,000 after acquiring an additional 208 shares during the last quarter. Columbus Macro LLC boosted its stake in shares of Astrazeneca by 2.1% during the 3rd quarter. Columbus Macro LLC now owns 16,262 shares of the company’s stock worth $2,648,000 after acquiring an additional 339 shares in the last quarter. Orca Wealth Management LLC boosted its stake in shares of Astrazeneca by 7.8% during the 3rd quarter. Orca Wealth Management LLC now owns 37,436 shares of the company’s stock worth $6,045,000 after acquiring an additional 2,720 shares in the last quarter. Triumph Capital Management grew its position in shares of Astrazeneca by 32.6% during the 3rd quarter. Triumph Capital Management now owns 252 shares of the company’s stock valued at $41,000 after acquiring an additional 62 shares during the period. Finally, Mitchell & Pahl Private Wealth LLC grew its position in shares of Astrazeneca by 6.1% during the 3rd quarter. Mitchell & Pahl Private Wealth LLC now owns 7,821 shares of the company’s stock valued at $1,263,000 after acquiring an additional 452 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Stock Up 4.1%

AZN stock opened at $162.21 on Monday. The firm has a 50 day moving average of $161.96 and a 200 day moving average of $176.37. The stock has a market capitalization of $251.57 billion, a PE ratio of 16.05, a price-to-earnings-growth ratio of 1.32 and a beta of 0.27. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. Astrazeneca has a 52 week low of $153.41 and a 52 week high of $212.71.

Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.13. The business had revenue of $15.38 billion for the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. Astrazeneca’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.17 EPS. Sell-side analysts forecast that Astrazeneca will post 9.38 earnings per share for the current year.

About Astrazeneca

(Get Free Report)

AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. Its research, development and commercial operations focus on prescription medicines for serious and chronic diseases, with an emphasis on discovering and delivering innovative therapies rather than operating as a diversified healthcare conglomerate.

The company’s principal therapeutic areas include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunological conditions; and rare diseases.